FAPi PET/CT scan for pancreatic ductal adenocarcinoma
FAP-1 Study: FAPi PET in Pancreatic Ductal Adenocarcinoma: A Prospective, Exploratory Study
This test uses a Gallium-68–labeled FAP inhibitor with PET/CT to see if it can detect tumor tissue and tumor-associated stroma in adults with biopsy-proven pancreatic ductal adenocarcinoma.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Tata Memorial Hospital Government |
| Locations | 1 site (Mumbai, Maharashtra) |
| Trial ID | NCT07342231 on ClinicalTrials.gov |
What this trial studies
This is an observational imaging protocol using Ga-68 FAPi PET/CT to visualize fibroblast activation protein (FAP) in and around pancreatic ductal adenocarcinoma. The tracer (a Gallium-68–labeled FAP inhibitor peptide) binds to FAP expressed in the tumor microenvironment and PET/CT images are acquired to map tracer uptake. Patients enrolled are adults with biopsy-proven pancreatic adenocarcinoma and without concurrent malignancy, and pregnant or lactating patients are excluded. Images will be compared to standard imaging to characterize additional tissue detection beyond conventional CT.
Who should consider this trial
Good fit: Adults over 18 with biopsy-proven pancreatic ductal adenocarcinoma who are willing to undergo Ga-68 FAPi PET/CT and have no other active cancers are ideal candidates.
Not a fit: Patients with concurrent malignancies, pregnant or lactating individuals, or tumors that do not express FAP may not receive added benefit from this imaging approach.
Why it matters
Potential benefit: If successful, this approach could help clinicians find more tumor and tumor-associated tissue than standard CT, potentially improving staging and treatment planning.
How similar studies have performed: Early clinical reports across several tumor types, including pancreatic cancer, have shown promising tumor visualization with FAPi PET, though large definitive outcome trials are limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Any gender with age more than 18 years * Patients with biopsy-proven pancreatic ductal adenocarcinoma * Patient willing to participate in study Exclusion Criteria: * Patient with concurrent malignancy * Pregnancy and lactation
Where this trial is running
Mumbai, Maharashtra
- Tata Memorial Hospital, Mumbai, India — Mumbai, Maharashtra, India (Recruiting)
Study contacts
- Principal investigator: Ameya Puranik, DNB — Tata Memorial Hospital, Mumbai
- Study coordinator: Sushil Yadav, MSc
- Email: sushilyadav.crc@gmail.com
- Phone: 912224177000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.